Studies have confirmed that patients with chronic hepatitis B,regularly treated with first-line nucleoside(acid)analogues for 48 weeks,exhibit a reduction in serum HBV DNA to less than 2 000 IU/mL,yet still persistently or intermittently higher than the lower limit of detection,indicating a state of low-level viremia(LLV).However,patients with LLV still have the risk of developing liver fibrosis,cirrhosis,liver cancer and even other end-stage liver diseases,which seriously threaten the life and health of patients.Therefore,LLV has become a hot and difficult point of antiviral therapy.At present,there is no strong evidence-based medicine treatment for LLV patients,and lack of relevant expert guidelines,consensus and other guidance.This article intends to review the research status of first-line nucleoside(acid)analogues in the treatment of LLV in patients with chronic hepatitis B,in order to provide reference for the diagnosis and treatment of such patients.
维普
万方数据